BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11312390)

  • 1. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.
    Robertson LP; Hickling P
    Rheumatology (Oxford); 2001 Apr; 40(4):473-4. PubMed ID: 11312390
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab treatment for severe orogenital ulceration in Behçet's disease.
    Connolly M; Armstrong JS; Buckley DA
    Br J Dermatol; 2005 Nov; 153(5):1073-5. PubMed ID: 16225632
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
    Almoznino G; Ben-Chetrit E
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of genital ulcers with infliximab in Behcet's disease.
    Haugeberg G; Velken M; Johnsen V
    Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract]   [Full Text] [Related]  

  • 6. [Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].
    Lestre S; Trindade F; Martins A; Baptista J; Feio AB; Lopes MJ
    Acta Reumatol Port; 2009; 34(4):633-40. PubMed ID: 20852576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.
    Aikawa NE; Gonçalves C; Silva CA; Gonçalves C; Bonfá E; de Carvalho JF
    Rheumatol Int; 2011 Aug; 31(8):1097-9. PubMed ID: 20012049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasculitis and oral and genital ulcers: Behçet's syndrome or HIV infection?
    Olivé A; Fuente MJ; Veny A; Romeu J
    Clin Exp Rheumatol; 1999; 17(1):124. PubMed ID: 10084048
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
    Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
    Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
    Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
    Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab.
    Madanat WY; Madanat AY
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S128-9. PubMed ID: 19026133
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
    Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
    Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
    Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
    Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
    Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS; Gavin MP; Sturrock RD
    Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Hotline. Oral allicin in the treatment of Behcet's disease through attenuating oxidative stress: A pilot study in 20 patients with mucocutaneous lesions.
    Zhong J; Xian D; Xiong X; Liu J
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab treatment of severe genital ulcers associated with Behçet disease.
    Kasugai C; Watanabe D; Mizutani K; Masuda Y; Zako M; Mukai T; Tamada Y; Matsumoto Y
    J Am Acad Dermatol; 2010 Jan; 62(1):162-164. PubMed ID: 20082903
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.